Affinage

POU2F2

POU domain, class 2, transcription factor 2 · UniProt P09086

Length
479 aa
Mass
51.2 kDa
Annotated
2026-06-10
33 papers in source corpus 27 papers cited in narrative 27 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 7/7 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

POU2F2 (OTF-2) is a POU-homeodomain transcription factor first identified as a B-cell factor that binds the octamer sequence 5'-ATGCAAAT and activates immunoglobulin gene transcription (PMID:3119226). It engages octamer-containing promoters through DNA contacts that are biochemically indistinguishable from the ubiquitous OTF-1, yet drives full B-cell-specific transcription only in cooperation with additional B-cell-restricted factors, indicating that promoter selectivity arises from combinatorial partnerships rather than intrinsic binding differences (PMID:2123291, PMID:2109187). High-level activation requires two structurally distinct transactivation domains — a C-terminal proline-rich domain and an upstream domain in which clustered glutamine and leucine residues are individually essential (PMID:2328729). Beyond immunoglobulin loci, POU2F2 octamer-dependently activates the MHC class II gene DRA (PMID:1560002), and its nuclear binding activity is modulated downstream of LPS and surface-Ig signaling, linking it to B-cell activation pathways (PMID:1689272, PMID:1658749). Loss-of-function mutations in POU2F2 contribute to follicular lymphoma pathogenesis (PMID:24435047). In neuronal development, Pou2f2 acts as a temporal transcription factor downstream of Onecut factors: in retina it represses the rod-fate determinant Nrl to expand cone production (PMID:32878923), and in spinal cord it operates within a sequential Onecut2→Pou2f2→Pou3f1 cascade controlling the chronological diversification of interneuron and motor neuron subtypes [PMID:31231191, PMID:31787878, PMID:bio_10.1101_2025.05.27.656404]. In cancer, POU2F2 functions broadly as an oncogenic transcriptional activator that directly binds and induces target promoters — including PDPK1, AGO1, PREX1, SPOCD1, MARCH1, ROBO1 and PIK3CD — to drive PI3K/AKT/mTOR signaling, aerobic glycolysis, proliferation and metastasis (PMID:26019213, PMID:33931589, PMID:33832481, PMID:39401868, PMID:40533483, PMID:40317800, PMID:41795741), and it also acts as a transcriptional repressor of SLC3A2 modulating ferroptosis (PMID:39251054).

Mechanistic history

Synthesis pass · year-by-year structured walk · 9 steps
  1. 1987 High

    Established the existence of a dedicated B-cell octamer-binding transcription factor for immunoglobulin genes, answering what protein activity drives kappa light chain transcription.

    Evidence Affinity purification to homogeneity, DNA-binding renaturation assay, and in vitro transcription from a kappa promoter

    PMID:3119226

    Open questions at the time
    • Did not define the activation domains or sequence of the factor
    • Cooperating B-cell-specific components not yet identified
  2. 1990 High

    Mapped how POU2F2 activates transcription, showing two structurally constrained transactivation domains rather than a single composition-dependent activator.

    Evidence Site-directed mutagenesis of OTF-2 cDNA with reporter assays in non-lymphoid cells

    PMID:2328729

    Open questions at the time
    • Coactivators contacted by each domain not identified
    • Structural basis of glutamine/leucine cluster requirement unresolved
  3. 1990 High

    Resolved the puzzle of why POU2F2 and ubiquitous OTF-1 bind octamers identically yet only POU2F2 confers B-cell-specific transcription, attributing specificity to cooperating B-cell factors.

    Evidence DNase footprinting, EMSA, and reconstituted in vitro transcription with purified factors in OTF-depleted extracts; identification of cooperating N-element factor (NTF)

    PMID:2109187 PMID:2123291

    Open questions at the time
    • NTF/cooperating factor not molecularly identified
    • Direct protein-protein contact with POU2F2 inferred but not demonstrated
  4. 1992 High

    Extended POU2F2 target repertoire beyond immunoglobulin genes to MHC class II, showing octamer-dependent activation distinct from OTF-1.

    Evidence In vitro reconstitution, recombinant protein, transfection, and octamer-element mutation of the DRA promoter

    PMID:1560002

    Open questions at the time
    • Genome-wide target scope unknown at this stage
    • Cell-type determinants of selectivity not addressed
  5. 1991 Medium

    Placed POU2F2 downstream of B-cell activation signals by linking its nuclear binding activity to LPS and surface-Ig crosslinking.

    Evidence EMSA and immunofluorescence on stimulated B cells, genetic variant cell line, reporter assays

    PMID:1658749 PMID:1689272

    Open questions at the time
    • Mechanism of signal-induced nuclear translocation not defined
    • Single-method localization evidence per finding
  6. 2014 Medium

    Implicated POU2F2 in human disease by showing lymphoma-associated mutations alter its transcriptional function.

    Evidence Exome sequencing, luciferase reporters, stable transduction, and expression profiling in follicular lymphoma

    PMID:24435047

    Open questions at the time
    • Causal driver status versus passenger mutation not fully resolved
    • Affected downstream gene programs only partly defined
  7. 2020 High

    Defined a developmental function as a temporal transcription factor, showing Pou2f2 represses Nrl to control cone-versus-rod photoreceptor fate timing.

    Evidence Promoter binding, conditional knockout, and retroviral misexpression in mouse retina with cone/rod quantification

    PMID:32878923

    Open questions at the time
    • Direct vs indirect repression mechanism at Nrl not fully dissected
    • Cofactors mediating repression unknown
  8. 2019 Medium

    Positioned Pou2f2 within an Onecut-controlled genetic cascade governing spinal interneuron and motor neuron diversification.

    Evidence Gain/loss-of-function in mouse spinal cord with interneuron marker immunofluorescence; preprint extension to motor neuron columns and a Onecut2→Pou2f2→Pou3f1 cascade

    PMID:31231191 PMID:31787878 PMID:bio_10.1101_2025.05.27.656404

    Open questions at the time
    • Direct transcriptional targets in neurons not identified
    • Spinal cord temporal cascade work partly preprint, not peer-reviewed
  9. 2025 Medium

    Established POU2F2 as a broad oncogenic transcriptional activator driving PI3K/AKT/mTOR signaling, glycolysis, proliferation and metastasis across diverse cancers via direct promoter activation of specific targets.

    Evidence ChIP, luciferase/dual-luciferase, DNA pulldown, knockdown with target reconstitution rescues, and xenograft/metastasis models across gastric, glioblastoma, lung, AML, breast, and other cancers

    PMID:26019213 PMID:33832481 PMID:33931589 PMID:38318853 PMID:39401868 PMID:40167268 PMID:40317800 PMID:40533483 PMID:41795741

    Open questions at the time
    • Unifying determinants of which targets POU2F2 selects in a given tissue unclear
    • Repressor versus activator mode switching mechanism (e.g. SLC3A2) not mechanistically explained
    • Most findings are single-lab, single-cancer studies

Open questions

Synthesis pass · forward-looking unresolved questions
  • How POU2F2 switches between transcriptional activation and repression and selects context-specific targets across immune, neuronal, and cancer settings remains unresolved.
  • No structural model linking cofactor binding to activator/repressor output
  • Genome-wide occupancy comparisons across cell types not integrated
  • Mechanism of upstream regulation (NF-κB, PPARγ, CBX7, miR-218) on POU2F2 levels incompletely defined

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0140110 transcription regulator activity 6 GO:0003677 DNA binding 4
Localization
GO:0005634 nucleus 2
Pathway
R-HSA-1266738 Developmental Biology 3 R-HSA-162582 Signal Transduction 3 R-HSA-1643685 Disease 3 R-HSA-168256 Immune System 3 R-HSA-74160 Gene expression (Transcription) 3
Partners
CEBPBHOXA11-ASRUNX1RUNX2

Evidence

Reading pass · 27 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
1987 POU2F2 (OTF-2) was purified to homogeneity from B cells as a protein complex of three peptides (62, 61, and 58.5 kDa), each capable of binding the octamer sequence 5'-ATGCAAAT, and the purified factor activated transcription from a kappa light chain promoter in vitro, establishing it as a B cell-specific transcription factor for immunoglobulin genes. Affinity chromatography purification, SDS-PAGE renaturation/DNA binding assay, in vitro transcription assay Cell High 3119226
1990 OTF-2 (POU2F2) contains two distinct transcriptional activation domains required jointly for high-level transcription: a C-terminal proline-rich domain and an upstream domain with intermingled proline, glutamine, and leucine residues; point mutations in either glutamine or leucine clusters abolished function, indicating structural constraints beyond amino acid composition alone. Site-directed mutagenesis of OTF-2 cDNA, transient transfection into non-lymphoid cells, reporter gene transcription assay The EMBO journal High 2328729
1990 Purified OTF-1 and OTF-2 (POU2F2) have indistinguishable DNA-binding affinities and protein-DNA contacts on immunoglobulin or histone H2b promoters, and each can intrinsically activate transcription from these promoters to equivalent levels in OTF-depleted extracts; however, full immunoglobulin gene transcription in B-cell extracts requires an additional B-cell-specific regulatory component that cooperates with OTF-2. High-resolution DNase I footprinting, electrophoretic mobility shift assay (EMSA), in vitro transcription with OTF-depleted extracts, purified protein reconstitution Molecular and cellular biology High 2123291
1990 OTF-2 (POU2F2) interacts with the octamer element of the MOPC 141 immunoglobulin heavy-chain promoter, with footprinting revealing contacts extending over the heptamer element; an additional novel B-cell factor (NTF) binding the N element (5'-GGAACCTCCCCC) cooperates with OTF-2 to drive high-level B-cell-specific transcription, suggesting protein-protein interactions between NTF and OTF-2. EMSA, DNase I footprinting, in vitro transcription assay with purified factors Molecular and cellular biology Medium 2109187
1990 In a variant B-lymphoma cell line (1.3E2) defective in LPS-mediated kappa gene activation, neither NF-κB nor OTF-2 nuclear localization increases upon LPS stimulation, indicating that OTF-2 nuclear translocation is part of the LPS-activated transcriptional pathway for kappa light chain expression in B cells. Electrophoretic mobility shift assay on nuclear extracts, genetic variant cell line analysis Immunogenetics Medium 1689272
1991 Anti-IgM antibody treatment of LPS-stimulated splenic B cells reduces OTF-2 (POU2F2) binding activity in nuclear extracts and alters its nuclear localization as detected by immunofluorescence, coinciding with suppression of IgH enhancer-driven transcription, placing OTF-2 downstream of surface Ig crosslinking signals. EMSA on nuclear extracts, in situ immunofluorescence with anti-OTF-2 antibodies, CAT reporter assay Nucleic acids research Medium 1658749
1992 OTF-2 (POU2F2), but not OTF-1, positively activates transcription of the MHC class II gene DRA in vitro and in vivo; this activation requires an intact octamer element in the DRA promoter, as demonstrated by protein fractions enriched for OTF-2, recombinant OTF-2 produced by in vitro transcription/translation, and transient transfection with an OTF-2 expression vector. In vitro transcription with OTF-enriched fractions, in vitro transcription/translation of recombinant OTF-2, transient transfection with OTF-2 expression vector, octamer element mutation analysis The Journal of biological chemistry High 1560002
2014 Mutations in POU2F2 (OCT2) found in follicular lymphoma affect its transcriptional and functional properties, as measured by luciferase reporter assays, biological analysis of stably transduced cell lines, and global expression profiling, indicating that loss-of-function mutations in POU2F2 contribute to lymphoma pathogenesis. Exome sequencing, luciferase reporter assay, stable cell line transduction, global expression profiling Blood Medium 24435047
2015 In gastric cancer cells, POU2F2 expression is induced by NF-κB activation; in turn, POU2F2 directly binds the ROBO1 promoter and activates its transcription, thereby promoting gastric cancer cell metastasis; miR-218 suppresses this axis by simultaneously targeting POU2F2, ROBO1, and IKK-β. Luciferase reporter assay, EMSA, ChIP-PCR, gain/loss-of-function experiments in vitro and in vivo (experimental metastasis animal model) Gut High 26019213
2020 In developing mouse retina, Pou2f2 (induced by Pou2f1) binds to a POU motif in the promoter of the rod-inducing factor Nrl to repress its expression; conditional inactivation of Pou2f2 in retinal progenitor cells increases Nrl expression and reduces cone photoreceptor production, while forced sustained Pou2f2 expression expands the cone production window. Promoter binding assay, conditional knockout mouse model (Cre-mediated), retroviral misexpression, quantification of cone vs. rod fate Development (Cambridge, England) High 32878923
2019 In the developing mouse spinal cord, Pou2f2 expression in V2 interneurons is restricted by Onecut transcription factors; gain- or loss-of-function of Pou2f2 alters the position (distribution/migration) of V2 interneuron populations, placing Pou2f2 downstream of Onecut factors in a genetic pathway controlling interneuron diversification. Gain-of-function and loss-of-function experiments in mouse spinal cord, immunofluorescence for interneuron markers Frontiers in cellular neuroscience Medium 31231191
2019 In the developing mouse spinal cord, Pou2f2 is expressed in dorsal interneurons under regulation by Onecut factors; overexpression or inactivation of Pou2f2 leads to alterations in dI2, dI3, and Phox2a-positive dI5 differentiation and defects in dI2–dI6 interneuron distribution. Gain-of-function and loss-of-function experiments, immunofluorescence for dorsal interneuron markers Frontiers in molecular neuroscience Medium 31787878
2021 POU2F2 promotes glioblastoma cell proliferation and aerobic glycolysis by directly binding to and activating transcription of the PDPK1 promoter; reconstitution of PDPK1 in POU2F2-knockdown cells rescues AKT/mTOR pathway activity, glycolysis, and proliferation, placing POU2F2 upstream of PDPK1 in a PI3K/AKT/mTOR signaling cascade. ChIP assay, luciferase reporter assay, shRNA knockdown, PDPK1 reconstitution/rescue experiments, PDPK1/AKT interaction inhibitor, in vivo xenograft model Cell death & disease High 33931589
2021 POU2F2 promotes lung cancer cell proliferation and motility by directly binding to and activating transcription of the AGO1 promoter, as demonstrated by ChIP and luciferase assays, with AGO1 knockdown abolishing the POU2F2-driven effects in vitro and in vivo. ChIP assay, luciferase reporter assay, shRNA knockdown, CCK-8/colony formation/Transwell assays, xenograft tumor model BMC pulmonary medicine Medium 33832481
2023 POU2F2 is a critical transcription factor driving escape from oncogene-induced senescence (OIS); its binding activity to cis-regulatory elements increases as cells escape OIS, and it exploits a pre-coded enhancer landscape to activate transcriptional programs enabling senescence escape and acquisition of transformed cell features. Dynamic multidimensional profiling (chromatin accessibility, transcriptomics), ChIP/CUT&RUN for POU2F2 binding, functional OIS escape assays Cell genomics Medium 37082139
2022 CBX7 downregulates POU2F2 expression in bladder cancer cells; POU2F2 in turn activates PD-L1 expression, establishing a CBX7/POU2F2/PD-L1 regulatory axis; depletion of CBX7 results in resistance to PD-1 blockade. RNA-seq, knockdown experiments, Western blot, functional PD-1 blockade resistance assay Biochemical and biophysical research communications Low 35526483
2023 POU2F2 and CEBPB cooperatively and additively enhance EDN1 (endothelin 1) transcription in vascular smooth muscle cells by binding to an enhancer region of the Edn1 promoter (-1309 to -1279 bp); overexpression of either factor increases EDN1 expression, and POU2F2 knockdown reduces it. Promoter activity analysis (luciferase), overexpression/knockdown experiments, EDN1 secretion ELISA Journal of molecular endocrinology Medium 36942826
2024 POU2F2 transcriptionally upregulates PTPRG-AS1 lncRNA in triple-negative breast cancer by binding to its promoter; PTPRG-AS1 then acts as a competing endogenous RNA to sponge miR-376c-3p, thereby upregulating SLC7A11 and inhibiting ferroptosis. ChIP assay, dual-luciferase reporter assay, MTT/colony formation assay, Fe2+/ROS measurement, in vivo tumor growth assay Epigenomics Medium 38318853
2024 POU2F2 promotes PIK3CD transcription by directly binding to its promoter in B lymphocytes, thereby activating the Akt/mTOR signaling pathway and enhancing B cell proliferation; knockdown of POU2F2 suppresses B cell proliferation and IgG deposition in vivo. ChIP assay, luciferase reporter assay, shRNA knockdown, MTT/flow cytometry, IgG deposition assessment, Western blot Nephrology (Carlton, Vic.) Medium 39401868
2024 POU2F2 acts as a transcriptional repressor of SLC3A2 in chondrocytes; lncRNA HOXA11-AS interacts with POU2F2 (identified by RNA pulldown, mass spectrometry, and ChIP) to block its repressor activity, thereby increasing SLC3A2 expression and inhibiting ferroptosis in osteoarthritis. RNA pulldown, mass spectrometry, ChIP, RNA sequencing, in vitro and in vivo OA models Cellular signalling Medium 39251054
2025 POU2F2 positively regulates transcription of the MARCH1 E3 ubiquitin ligase gene by binding its promoter; MARCH1 in turn interacts with and promotes ubiquitination and degradation of the tumor suppressor MYCT1, thereby driving AML cell proliferation and inhibiting apoptosis and differentiation. Promoter binding assay (ChIP/luciferase inferred from context), gain/loss-of-function, co-immunoprecipitation, ubiquitination assay, in vivo AML mouse model Oncogene Medium 40533483
2025 POU2F2 directly binds the PREX1 promoter and activates its transcription in AML cells, promoting mTOR pathway activation and AML malignant progression; PREX1 knockdown reverses POU2F2 overexpression-driven effects, establishing POU2F2 upstream of PREX1/mTOR in AML. Dual-luciferase assay, ChIP assay, Western blot, colony formation/CCK-8/Transwell assays, xenograft tumor model Journal of biochemical and molecular toxicology Medium 40317800
2025 In the THBS1-mediated diabetic osteoporosis pathway, PPARγ (activated downstream of CD36) transcriptionally upregulates POU2F2, which then enhances osteoclastogenesis via c-FOS induction; genetic ablation of THBS1 or virtual screening inhibitor nasunin suppressed this CD36-PPARγ-POU2F2-c-FOS axis and reduced bone loss in T2D mice. ChIP-qPCR for PPARγ binding to POU2F2 promoter, Western blot, flow cytometry, TRAP staining, micro-CT, in vivo T2D mouse model, virtual screening Biochimica et biophysica acta. Molecular basis of disease Medium 41407214
2025 In multiple myeloma, POU2F2 binds eccANKRD28 (an active enhancer eccDNA) and forms a protein complex with RUNX1 and RUNX2 to activate the promoters of oncogenes including IRF4, JUNB, IKZF3, RUNX3, and BCL2, driving bortezomib/lenalidomide resistance; CRISPR/Cas9-mediated elevation of eccANKRD28 desensitizes cells to treatment. H3K27ac ChIP-seq, scRNA-seq, scATAC-seq, CUT&Tag, CRISPR/Cas9, in vitro and in vivo drug resistance assays Advanced science (Weinheim, Baden-Wurttemberg, Germany) Medium 40167268
2026 POU2F2 is a crucial transcription factor mediating MIF-driven activation of SPP1+ tumor-associated macrophages in colorectal cancer; BCL9L is identified as a direct downstream transcriptional target of POU2F2 in this context, and blocking MIF signaling abolishes SPP1+TAM activation in vitro and in vivo. scRNA-seq interaction analysis, TAM co-culture model, liver metastasis in vivo model, mechanistic studies identifying POU2F2 as transcriptional regulator of BCL9L International journal of biological sciences Low 41800265
2026 POU2F2 directly binds to and activates the SPOCD1 promoter in lung adenocarcinoma cells (demonstrated by dual-luciferase, ChIP, and DNA pulldown assays), thereby enhancing PI3K/AKT pathway signaling and promoting cell proliferation; exercise suppresses POU2F2 expression, disrupting this axis. Dual-luciferase assay, ChIP assay, DNA pulldown, shRNA knockdown, CCK-8/EdU/flow cytometry/TUNEL assays, xenograft model with Ki67 IHC Clinical & translational oncology Medium 41795741
2025 Genetic loss of Pou2f2 in mouse spinal cord results in impaired development of two early-born motor neuron columns and re-specification of anterolateral system projection neurons as a later-born subset, placing Pou2f2 in a conserved sequential transcription factor cascade (Onecut2 → Pou2f2 → Pou3f1) that controls chronological diversification of spinal neuron subtypes. Conditional/constitutive mouse knockout, immunofluorescence for motor neuron and projection neuron markers, genetic epistasis analysis bioRxivpreprint Medium bio_10.1101_2025.05.27.656404

Source papers

Stage 0 corpus · 33 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
1987 Identification and purification of a human lymphoid-specific octamer-binding protein (OTF-2) that activates transcription of an immunoglobulin promoter in vitro. Cell 349 3119226
2014 Mutations in linker histone genes HIST1H1 B, C, D, and E; OCT2 (POU2F2); IRF8; and ARID1A underlying the pathogenesis of follicular lymphoma. Blood 147 24435047
1990 The cell type-specific octamer transcription factor OTF-2 has two domains required for the activation of transcription. The EMBO journal 136 2328729
1988 Drosophila homoeotic genes encode transcriptional activators similar to mammalian OTF-2. Nature 109 2904655
1990 Activation of octamer-containing promoters by either octamer-binding transcription factor 1 (OTF-1) or OTF-2 and requirement of an additional B-cell-specific component for optimal transcription of immunoglobulin promoters. Molecular and cellular biology 102 2123291
1991 Chromosomal location of the octamer transcription factors, Otf-1, Otf-2, and Otf-3, defines multiple Otf-3-related sequences dispersed in the mouse genome. Genomics 75 1676977
2021 POU2F2 regulates glycolytic reprogramming and glioblastoma progression via PDPK1-dependent activation of PI3K/AKT/mTOR pathway. Cell death & disease 60 33931589
2015 POU2F2-oriented network promotes human gastric cancer metastasis. Gut 57 26019213
2020 Pou2f1 and Pou2f2 cooperate to control the timing of cone photoreceptor production in the developing mouse retina. Development (Cambridge, England) 53 32878923
2023 Escape from oncogene-induced senescence is controlled by POU2F2 and memorized by chromatin scars. Cell genomics 38 37082139
2019 Onecut Factors and Pou2f2 Regulate the Distribution of V2 Interneurons in the Mouse Developing Spinal Cord. Frontiers in cellular neuroscience 26 31231191
2012 The chemoselective reactions of tyrosine-containing G-protein-coupled receptor peptides with [Cp*Rh(H2O)3](OTf)2, including 2D NMR structures and the biological consequences. Journal of the American Chemical Society 25 22671299
1990 1.3E2, a variant of the B lymphoma 70Z/3, defective in activation of NF-kappa B and OTF-2. Immunogenetics 19 1689272
1990 Identification of a novel factor that interacts with an immunoglobulin heavy-chain promoter and stimulates transcription in conjunction with the lymphoid cell-specific factor OTF2. Molecular and cellular biology 19 2109187
2021 Long Non-Coding RNA ARAP1-AS1 Facilitates the Progression of Cervical Cancer by Regulating miR-149-3p and POU2F2. Pathobiology : journal of immunopathology, molecular and cellular biology 18 33965958
1991 Anti-IgM antibodies down modulate mu-enhancer activity and OTF2 levels in LPS-stimulated mouse splenic B-cells. Nucleic acids research 18 1658749
2024 POU2F2-mediated upregulation of lncRNA PTPRG-AS1 inhibits ferroptosis in breast cancer via miR-376c-3p/SLC7A11 axis. Epigenomics 17 38318853
2021 POU2F2 promotes the proliferation and motility of lung cancer cells by activating AGO1. BMC pulmonary medicine 17 33832481
1992 The B cell-specific nuclear factor OTF-2 positively regulates transcription of the human class II transplantation gene, DRA. The Journal of biological chemistry 15 1560002
2019 Pou2f2 Regulates the Distribution of Dorsal Interneurons in the Mouse Developing Spinal Cord. Frontiers in molecular neuroscience 11 31787878
2025 Enhancer Extrachromosomal Circular DNA ANKRD28 Elicits Drug Resistance via POU2F2-Mediated Transcriptional Network in Multiple Myeloma. Advanced science (Weinheim, Baden-Wurttemberg, Germany) 8 40167268
2024 LncRNA HOXA11-AS intercepts the POU2F2-mediated downregulation of SLC3A2 in osteoarthritis to suppress ferroptosis. Cellular signalling 7 39251054
2023 CEBPB/POU2F2 modulates endothelin 1 expression in prehypertensive SHR vascular smooth muscle cells. Journal of molecular endocrinology 7 36942826
2019 Overexpressing of POU2F2 accelerates fracture healing via regulating HMGA1/Wnt/β-catenin signaling pathway. Bioscience, biotechnology, and biochemistry 6 31782345
2025 POU2F2+ B cells enhance antitumor immunity and predict better survival in non small cell lung cancer. Scientific reports 5 39994401
2022 CBX7 represses the POU2F2 to inhibit the PD-L1 expression and regulate the immune response in bladder cancer. Biochemical and biophysical research communications 5 35526483
2025 MARCH1, transcriptionally regulated by POU2F2, facilitates acute myeloid leukemia progression via inducing MYCT1 degradation. Oncogene 2 40533483
2018 A Switch from Mechanistic Competition Mediated by a Combination of Temperature and Concentration Effects in the Oxidation Reaction of [FeII (N4Py/TPA)](OTf)2. Chemistry (Weinheim an der Bergstrasse, Germany) 2 29889323
2025 Upregulation of PREX1 Expression by POU2F2 Promotes the Malignant Progression of Acute Myeloid Leukemia via the mTOR Pathway. Journal of biochemical and molecular toxicology 1 40317800
2024 POU2F2 activates the Akt/mTOR signalling pathway and enhances B lymphocyte function during diabetic kidney disease by promoting PIK3CD transcription. Nephrology (Carlton, Vic.) 1 39401868
2026 Exercise inhibits proliferation and induces apoptosis of lung adenocarcinoma cells via the POU2F2-SPOCD1-PI3K/AKT signaling axis. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 0 41795741
2026 CD44/POU2F2/BCL9L axis mediates MIF-driven SPP1+TAM activation in colorectal cancer metastasis. International journal of biological sciences 0 41800265
2025 Neutrophil-derived thrombospondin-1 (THBS1) drives type 2 diabetes-induced osteoporosis via CD36-PPARγ-POU2F2 signaling. Biochimica et biophysica acta. Molecular basis of disease 0 41407214

Missed literature

Know a paper Affinage missed for POU2F2? Flag it for the maintainers and the community.

No submissions yet.